Cardiovascular disease in metabolic-associated fatty liver disease.

PURPOSE OF REVIEW: Fatty liver disease is increasingly common worldwide and is associated with an increased risk of cardiovascular disease (CVD).

RECENT FINDINGS: This review describes the cardiovascular outcomes, clinical assessment and management as well as the impact of emerging drug treatment on CVD risk.

SUMMARY: Patients with fatty liver require CVD risk assessment including consideration of statin therapy. Emerging therapeutic drugs for fatty liver may have both adverse and beneficial effects on CVD risk.